Steven P. Treon, MD, MA, PhD, Professor of Medicine, Harvard Medical School, Boston, Massachusetts, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with Waldenström macroglobulinemia with MYDD88 and CXCR4 mutations. These data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting.

Click the link below to read the transcript and/or view the video: